Sector
PharmaceuticalsOpen
₹21.11Prev. Close
₹20.7Turnover(Lac.)
₹0.67Day's High
₹21.11Day's Low
₹21.1152 Week's High
₹29.2152 Week's Low
₹4.68Book Value
₹0.98Face Value
₹10Mkt Cap (₹ Cr.)
12.43P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.43 | -5.3 | -5.14 | -5.14 |
Net Worth | 1.1 | 1.23 | 1.39 | 1.39 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.05 | -0.09 | -0.07 | -0.03 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Profit before tax | -0.23 | -0.31 | 0 | -0.06 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.09 | -2.52 | -0.16 | 0.01 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -31.43 | 166.89 | 31.01 | 18.5 |
EBIT growth | -24.06 | 15,191.52 | -96.91 | 110.74 |
Net profit growth | -24.1 | 15,171.95 | -96.92 | 110.79 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,823.35 | 157.3 | 4,37,806.65 | 237.82 | 0.74 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,140.8 | 81.93 | 1,36,080.52 | 430 | 0.58 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,611.9 | 33.1 | 1,31,478.83 | 1,055.94 | 0.8 | 3,752.25 | 346.4 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,417 | 77.52 | 1,16,513.07 | 469 | 0.81 | 2,394 | 201.77 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,100.5 | 25.69 | 1,12,205.15 | 1,700.8 | 0.27 | 4,035.4 | 156.19 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Prakash Shah
Director
Ganpat Dhondu Salekar
Independent Director
Shirish Shetye
Independent Director
Parul Dave
Company Sec. & Compli. Officer
Bhavana Tak
Additional Director
Avani Savjibhai Godhaniya
Additional Director
Dinesh Chander Notiyal
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bacil Pharma Ltd
Summary
Incorporated as a private limited company in Maharashtra in May 87, Bacil Pharma (BPL) was converted into a public limited company in Oct.90. The main business activity of the Company is Pharmaceutical.Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India. The company has strong field force of 500 plus, spread over various States and Districts. It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage. To augment the domestic market, Companys operations are based on focused approach.Multi-Speciality division Vibrant specialises in various specialties, like Anti-Infectives, Pain Management, Respiratory Care, Womens Health, to name a few. Aziwin, Ebay, Balvibe, MNF, Ocium and Monogesic Plus Gel (Innovative Pain Relieving Gel, first time in India) are some of the leading brands in the respective segments. Bal Vedics Division integrates modern medicine with herbal/ayurvedic preparation targeting specific conditions like, Prostrate Enlargement, Renal Calculi, Male Infertility, Women Health etc. Bal Pharma Institutional division is associated with the top Government bodies and Hospitals to extend its product range to the masses. Every area is well covered and supplied through there channel partners.Bal Pharma Unit - 1, is a finished dosage f
Read More
The Bacil Pharma Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹21.11 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bacil Pharma Ltd is ₹12.43 Cr. as of 06 Sep ‘24
The PE and PB ratios of Bacil Pharma Ltd is 0 and 21.02 as of 06 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Bacil Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bacil Pharma Ltd is ₹4.68 and ₹29.21 as of 06 Sep ‘24
Bacil Pharma Ltd's CAGR for 5 Years at 54.13%, 3 Years at 46.01%, 1 Year at 182.02%, 6 Month at 89.56%, 3 Month at -22.79% and 1 Month at 1.47%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice